Systematic review with meta‐analysis: the accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or psychological markers
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Summary: Background: Irritable bowel syndrome ( IBS ) is a complex, heterogeneous disease which can be challenging to diagnose. No study has identified and assessed the accuracy of all available methods of diagnosing IBS . Aim: To conduct a systematic review of the literature to identify and assess accuracy of symptom‐based diagnostic criteria, biomarkers, psychological markers or combinations thereof. Methods: MEDLINE , EMBASE and EMBASE Classic were searched (until April 2015) to identify studies reporting accuracy of available methods to diagnose IBS in adult populations. Eligible studies assessed accuracy of these diagnostic tests against an accepted reference standard. Data were extracted to calculate positive and negative likelihood ratios, with 95% confidence intervals ( CI s), of the diagnostic test utilised. Where more than one study used the same test, data were pooled in a meta‐analysis. Results: Twenty‐two studies (7106 patients) were eligible. Positive and negative likelihood ratios of the current gold standard, the Rome III criteria, were 3.35 (95% CI : 2.97–3.79) and 0.39 (95% CI : 0.34–0.46), similar to other symptom‐based criteria. Eleven biomarkers performed no better than symptom‐based criteria. Psychological markers performed well in one study. Five different combinations were assessed. The best in terms of positive likelihood ratio was faecal calprotectin, intestinal permeability and Rome I criteria (26.4; 95% CI : 11.4–61.9), and in terms of negative likelihood ratio serum‐based biomarkers and psychological markers (0.18; 95% CI : 0.12–0.25). Conclusions: Symptom‐based diagnostic criteria, biomarkers and psychological markers performed modestly in predicting IBS . Combining symptoms with markers appears more effective, and may represent the way forward in the diagnosis of IBS .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., Leeflang, M. M. G., Sterne, J. A. C., Bossuyt, P. M. M., & the QUADAS-2 Group* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-8-201110180-00009 · Cited by 14,199
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis
Lovell, R. M., & Ford, A. C. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.02.029 · Cited by 2,155
Self-citationEmpirical evidence of design-related bias in studies of diagnostic tests.
Lijmer, J. G. (1999) · JAMA · doi:10.1001/jama.282.11.1061 · Cited by 1,861 · cited 1×
“because these are subject to spectrum bias as the study design often omits mild cases that are difficult to diagnose.(43) Finally, 14 of the 22 eligible studies were judged as high risk of bias, or had other applicability concerns, when assessing quality using the QUADAS-2 tool, highlighting the limitations of some of…”
Kassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., Malinen, E., Apajalahti, J., & Palva, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.005 · Cited by 1,002
Medically Unexplained Physical Symptoms, Anxiety, and Depression: A Meta-Analytic Review
Henningsen, P., Zimmermann, T., & Sattel, H. (2003) · Psychosomatic Medicine · doi:10.1097/01.psy.0000075977.90337.e7 · Cited by 829
Halpin, S. J., & Ford, A. C. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.260 · Cited by 607
Self-citationReview article: the economic impact of the irritable bowel syndrome
Canavan, C., West, J., & Card, T. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12938 · Cited by 458 · cited 1×
“There is an estimated direct cost per patient to the US economy of between $742 and $7547.(3) The pathogenesis of IBS is poorly understood and, as yet, no unifying structural or physiological cause has been identified.”
BackgroundTillisch, K., Mayer, E. A., & Labus, J. S. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.07.053 · Cited by 412
Sanders, D. S., Carter, M. J., Hurlstone, D. P., Pearce, A., Ward, A. M., McAlindon, M. E., & Lobo, A. J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06581-3 · Cited by 390
Cited by
Kelly, J. R., Kennedy, P. J., Cryan, J. F., Dinan, T. G., Clarke, G., & Hyland, N. P. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00392 · Cited by 1,110
ACG Clinical Guideline: Management of Irritable Bowel Syndrome
Lacy, B. E., Pimentel, M., Brenner, D. M., Chey, W. D., Keefer, L. A., Long, M. D., & Moshiree, B. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001036 · Cited by 893
Development and Validation of the Rome IV Diagnostic Questionnaire for Adults
Palsson, O. S., Whitehead, W. E., van Tilburg, M. A. L., Chang, L., Chey, W., Crowell, M. D., Keefer, L., Lembo, A. J., Parkman, H. P., Rao, S. S. C., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.014 · Cited by 719
Ford, A. C., Lacy, B. E., & Talley, N. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1607547 · Cited by 587
Self-citationBlack, C. J., Craig, O., Gracie, D. J., & Ford, A. C. (2021) · Gut · doi:10.1136/gutjnl-2020-322519 · Cited by 86
Self-citationShankar, V., Reo, N. V., & Paliy, O. (2015) · Microbiome · doi:10.1186/s40168-015-0139-9 · Cited by 26
Metadata
- Authors
- Sood, R., Gracie, D. J., Law, G. R., & Ford, A. C.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2015-06-15
- Volume
- 42
- Issue
- 5
- Pages
- 491-503
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W1764139713
- Cited by
- 86
- References
- 13
- FWCI
- 2.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.